Cardiology

As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

Researchers aimed to discover whether pharmacist-led delivery of oral anticoagulation therapy can lead to an increase in stroke risk reduction for patients with actionable atrial fibrillation.

When used together, sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were able to lower the risk of major adverse cardiovascular events and kidney disease by 11% and 33%, respectively.

Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.

In 2 abstracts presented at ASCO 2024, researchers addressed the use of GLP-1s for weight loss and to reduce cardiovascular outcomes in women with breast cancer.

In a session presented at the 2024 Heart in Diabetes Conference, Neha Pagidipati, MD, MPH, discussed weight change and its effects on cardiovascular complications.

In abstracts presented at the 2024 American Society of Clinical Oncology’s annual meeting, researchers addressed the association between heart failure and multiple types of cancers.

While elevated BMI at baseline was not associated with increased cardiovascular risk, cumulative excess BMI was associated with an increased risk in people under 50.

After 24 weeks of participation in an AI-driven lifestyle coaching program, 78% of all participants achieved a clinically meaningful SBP reduction of 5 mm Hg or greater.

Semaglutide reduced the risk of major kidney disease and cardiovascular (CV) events, and death from any cause, while simultaneously decelerating the loss of kidney function, among patients with type 2 diabetes (T2D) and CKD compared to placebo.

Despite a wealth of knowledge, pharmacists are frequently not consulted as part of the decision-making team in atrial fibrillation management.

Japan’s health ministry has issued a warning to consumers regarding red yeast rice dietary supplements containing a red species of mold after 5 people died and more were hospitalized after consumption.

The approval of vadadustat (Vafseo) from Akebia Therapeutics was based on data from the phase 3 INNO2VATE program.

Researchers detailed the FDA’s recommendations on low-dose aspirin and pharmacists’ role in cardiovascular practice transformation programs.

The drug had previously been granted a breakthrough therapy designation by the FDA.

The approval represents the first non-statin treatment indicated to lower low-density lipoprotein for primary prevention patients.

Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.

The latest guidelines advise managing obesity first, then treating a patient’s other conditions to produce optimal outcomes.

Hypertension remains a significant problem in areas of the rural South.

Recent studies on daylight saving time’s association with increased health risks have heightened the debate on whether to observe the biannual event or switch to one universal time.

Study results demonstrated the efficacy of semaglutide (Wegovy) in reducing cardiovascular risks in adults with overweight or obesity without diabetes.

Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.

Analysis of participants who never used tobacco cigarettes showed that daily cannabis use was associated a higher risk of both heart attack and stroke.

Study results suggesting that long-term cumulative use of attention-deficit/hyperactivity disorder (ADHD) medication increases the risk of CVD could prompt potential adjustments in treatment approaches for ADHD.